Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Foamix Pharma Ord (FOMX)

Foamix Pharma Ord (FOMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Foamix Pharma Ord 2 HOLZMAN ST. WEIZMANN SCIENCE PARK REHOVOT L3 76704 ISR

www.foamix.com P: 972-8931-6233

Description:

Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel.

Key Statistics

Overview:

Market Capitalization, $K 184,130
Shares Outstanding, K 61,582
Annual Sales, $ 3,600 K
Annual Net Income, $ -74,160 K
60-Month Beta 1.66
% of Insider Shareholders 2.95%
% of Institutional Shareholders 46.46%
Float, K 59,765
% Float 97.05%

Growth:

1-Year Return -21.73%
3-Year Return -67.43%
5-Year Return -70.69%
5-Year Revenue Growth 157.14%
5-Year Earnings Growth -672.73%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 03/12/20
Earnings Per Share ttm -1.04
EPS Growth vs. Prev Qtr -17.14%
EPS Growth vs. Prev Year -7.89%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

FOMX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -100.58%
Return-on-Assets % -81.39%
Profit Margin % -2,060.00%
Debt/Equity 0.24
Price/Sales 593.97
Price/Cash Flow N/A
Price/Book 3.41
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar